Altimmune, Inc.ALTNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -86.49% | +0.00% | +0.00% | +0.00% | +420.00% |
| Gross Profit Growth | -86.49% | +0.00% | +0.00% | -299200.00% | +420.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +22.33% | +6.70% | +14.88% | +25.79% | +41.19% |
| Weighted Average Shares Diluted Growth | +21.93% | +6.70% | +14.88% | +25.79% | +41.19% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -35.77% | -4.46% | -70.85% | -95.66% | -60.89% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -33.87% | -16.51% | +9.81% | +47.74% | +100.95% |
| Book Value per Share Growth | -47.98% | -22.96% | -7.91% | +10.62% | +28.97% |
| Debt Growth | +150.52% | +187.50% | +751.18% | +797.07% | +2023.02% |
| R&D Expense Growth | +16.99% | -26.34% | -18.53% | -24.46% | -6.94% |
| SG&A Expenses Growth | +17.50% | +12.82% | +1.72% | +18.82% | +106.48% |